KLRK1 and metastatic neoplasm: Release of soluble NKG2D-Ls is common in advanced cancer and high serum levels of soluble NKG2D-Ls correlate with a systemic reduction of NKG2D expression and with high cancer stage, metastatic disease and overall poor prognosis (20, 65–67).